Your browser doesn't support javascript.
loading
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.
Hayashi, Toshinobu; Yamamoto, Shun; Miyata, Yoshiharu; Takeda, Masayuki; Abe, Masakazu; Wada, Makoto; Iino, Keiko; Akechi, Tatsuo; Imamura, Chiyo K; Okuyama, Ayako; Ozawa, Keiko; Kim, Yong-Il; Sasaki, Hidenori; Satomi, Eriko; Tanaka, Ryuhei; Nakajima, Takako Eguchi; Nakamura, Naoki; Nishimura, Junichi; Noda, Mayumi; Hayashi, Kazumi; Higashi, Takahiro; Boku, Narikazu; Matsumoto, Koji; Matsumoto, Yoko; Okita, Kenji; Yamamoto, Nobuyuki; Aogi, Kenjiro; Iihara, Hirotoshi.
Afiliación
  • Hayashi T; Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. toshinobu@fukuoka-u.ac.jp.
  • Yamamoto S; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Miyata Y; Department of Artificial Intelligence and Digital Health Science, Kobe University Graduate School of Medicine, 7-1-48 Minatojimaminamimachi, Chuo-ku, Kobe, 650-0047, Japan.
  • Takeda M; Department of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
  • Abe M; Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
  • Wada M; Department of Psycho-Oncology, Osaka International Cancer Institute, 3-1-69 Chuo-Ku, Osaka, 541-8567, Japan.
  • Iino K; School of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
  • Akechi T; Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
  • Imamura CK; Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan.
  • Okuyama A; Graduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-Cho, Chuo-Ku, Tokyo, 104-0044, Japan.
  • Ozawa K; Division of Survivorship Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
  • Kim YI; Division of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-Ku, Osaka, Osaka, 533-0024, Japan.
  • Sasaki H; Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
  • Satomi E; Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
  • Tanaka R; Department of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
  • Nakajima TE; Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara-Cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Nakamura N; Department of Radiation Oncology, St. Marianna University, 2-16-1, Sugao, Miyamae, Kawasaki, 216-8511, Japan.
  • Nishimura J; Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Osaka, 541-8567, Japan.
  • Noda M; Non-Profit Organizaition Sasaeau-KaiAlpha, 518-7 Kawado-Cho, Chuo-Ku, Chiba, Chiba, 260-0802, Japan.
  • Hayashi K; Department of Clinical Oncology and Hematology, Jikei University School of Medicine, 3-25-8 Nishi-Shinnbashi Minatoku, Tokyo, 105-8461, Japan.
  • Higashi T; Department of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
  • Boku N; Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4-6-1 Shiroganedai, Minato-Ku, Tokyo, 108- 8639, Japan.
  • Matsumoto K; Division of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-Cho, Akashi, Hyogo, 673-0021, Japan.
  • Matsumoto Y; Non-Profit Organization Ehime Cancer Support Orange-No-Kai, 3-8-24 Furukawaminami, Matsuyama, Ehime, 790-0943, Japan.
  • Okita K; Department of Surgery, Otaru Ekisaikai Hospital, 1-4-1 Inaho, Otaru, Hokkaido, 047-0032, Japan.
  • Yamamoto N; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641-8509, Japan.
  • Aogi K; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan.
  • Iihara H; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Int J Clin Oncol ; 2024 Sep 11.
Article en En | MEDLINE | ID: mdl-39259324
ABSTRACT

BACKGROUND:

Chemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT3RAs) and corticosteroids provides clinically meaningful benefits in preventing CINV in patients receiving moderately emetogenic chemotherapy (MEC).

METHODS:

We conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT3RAs and dexamethasone for managing CINV in MEC. The endpoints were complete response (CR), complete control (CC), total control (TC), adverse events, and costs. The data were analyzed using a random effects model.

RESULTS:

From 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD] 0.11, 95% confidence interval [CI] 0.06-0.17) and delayed (RD 0.08, 95% CI 0.02-0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.

CONCLUSIONS:

Adding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Int J Clin Oncol / Int. j. clin. oncol / International journal of clinical oncology Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Int J Clin Oncol / Int. j. clin. oncol / International journal of clinical oncology Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article